TY - JOUR
T1 - Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus
AU - Dejnirattisai, Wanwisa
AU - Supasa, Piyada
AU - Wongwiwat, Wiyada
AU - Rouvinski, Alexander
AU - Barba-Spaeth, Giovanna
AU - Duangchinda, Thaneeya
AU - Sakuntabhai, Anavaj
AU - Cao-Lormeau, Van Mai
AU - Malasit, Prida
AU - Rey, Felix A.
AU - Mongkolsapaya, Juthathip
AU - Screaton, Gavin R.
N1 - Publisher Copyright:
© 2016 Nature America, Inc.
PY - 2016/8/19
Y1 - 2016/8/19
N2 - Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barré syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.
AB - Zika virus (ZIKV) was discovered in 1947 and was thought to lead to relatively mild disease. The recent explosive outbreak of ZIKV in South America has led to widespread concern, with reports of neurological sequelae ranging from Guillain Barré syndrome to microcephaly. ZIKV infection has occurred in areas previously exposed to dengue virus (DENV), a flavivirus closely related to ZIKV. Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection. Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed that most antibodies that reacted to DENV envelope protein also reacted to ZIKV. Antibodies to linear epitopes, including the immunodominant fusion-loop epitope, were able to bind ZIKV but were unable to neutralize the virus and instead promoted ADE. Our data indicate that immunity to DENV might drive greater ZIKV replication and have clear implications for disease pathogenesis and future vaccine programs for ZIKV and DENV.
UR - http://www.scopus.com/inward/record.url?scp=84976292755&partnerID=8YFLogxK
U2 - 10.1038/ni.3515
DO - 10.1038/ni.3515
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27339099
AN - SCOPUS:84976292755
SN - 1529-2908
VL - 17
SP - 1102
EP - 1108
JO - Nature Immunology
JF - Nature Immunology
IS - 9
ER -
